We are tracking news and moves in shares of Affymax, Inc. (NASDAQ: AFFY), Celldex Therapeutics ... has just announced it has agreed to be acquired by Attachmate Corporation. The stock is up $0.41 to $6.00, relative to a 52 …
Operating Expense ratio at 11.18. 3. Affymax, Inc. (AFFY): Engages in the development of drugs for the treatment of serious and life-threatening conditions. Over the last two weeks, the stock's Put/Call ratio changed from 0.68 to 0.27 …
(Reuters) - Shares of Affymax Inc AFFY.O fell 85 percent after it said serious adverse reactions ... cutting his rating on the stock to “hold” from “buy”. If the U.S. Food and Drug Administration were to withdraw its marketing approval for …
s=AFFY has an alert for $AFFY ... Emerging Stocks to Buy - J Charles Assets We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
Affymax /quotes/zigman/104161 /quotes/nls/affy AFFY plunged by more than 57% to $1.25 ... But Raymond didn’t cut his neutral rating on the stock — which he dubbed Affymax shares in February. There are slight possibilities for the …
--(BUSINESS WIRE)--Affymax, Inc. (AFFY), a biopharmaceutical company ... based on 37,490,095 shares of common stock outstanding as of April 30, 2014 and the remaining cash of approximately $4 million as of May 2014. Plan of …
AFFY was trading around $4.68 when we alerted readers to the stock in November 2011, and based on Thursday's (Jan.12) closing price of $6.95, it is up 48%. Affymax is co-developing Peginesatide with Takeda Pharmaceutical Co. Ltd. for the …
Affymax, Inc. (Nasdaq:AFFY), today announced the pricing of an underwritten public offering of 8,474,576 shares of its common stock at a price to the public of $5.90 per share. The gross proceeds to Affymax from this offering are …